TheProfitWatch

AKRO - Akero Therapeutics, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
54.38 -0.08 (-0.14%) -0.01 (-0.01%) 0.01 (0.01%) -0.01 (-0.01%) -0.04 (-0.07%) 0.02 (0.05%) --- -0.04 (-0.07%)

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.86
Diluted EPS:
-0.86
Basic P/E:
-63.1453
Diluted P/E:
-63.1453
RSI(14) 1m:
53.42
VWAP:
54.31
RVol:

Events

Period Kind Movement Occurred At

Related News